Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure

American Journal of Cardiology

Volumn 91, Issue 2, 2003, Pages 169-174

  Gattis, Wendy A ^a,b,c   O'Connor, Christopher M ^a,b,c   Leimberger, Jeffrey D ^a,b,c   Felker, G Michael ^a,b,c   Adams Jr , Kirkwood F ^a,b,c   Gheorghiade, Mihai ^a,b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MILRINONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; CARDIOTONIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMAN; MALE; METOPROLOL; MIDDLE AGE; MILRINONE; PROPANOLAMINES; STROKE VOLUME; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME;

EID: 0037298688     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03104-1     Document Type: Article

References (7)

1. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 334:1996;1349-1355.
2. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007.
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial. Lancet. 353:1999;9-13.
4. Packer M., Coats A.J.S., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., Demets D.L. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
5. Cuffe M.S., Califf R.M., Adams K.F., Bourge R.C., Colucci W., Massie B., O'Connor C.M., Pina I., Quigg R., Silver M., et al. Rationale and design of the OPTIME CHF trial outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J. 139:2000;15-22.
6. Cuffe M.S., Califf R.M., Adams K.F., Benza R., Bourge R., Colucci W.S., Massie B.M., O'Connor C.M., Pina I., Quigg R., Silver M.A., Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure a randomized controlled trial. JAMA. 287:2002;1541-1547.
7. O'Connor C.M., Gattis W.A., Zannad F., McNulty S.E., Gheorghiade M., Adams K.F., Califf R.M., McKenna W.J., Soler-Soler J., Swedberg K. Beta-blocker therapy in advanced heart failure clinical characteristics and long-term outcomes. Eur J Heart Failure. 1:1999;81-88.